A phase Ib, open-label, ascending dose study with step-up doses to assess safety, tolerability, and pharmacokinetics of PIT565 in participants with systemic lupus erythematosus (SLE)

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510025-14-00

Acronym

CPIT565B12101

Enrollment

Registered

2024-09-09

Start date

2024-10-08

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

None listed

Sex/Gender

All

Age

18 Years to No maximum

Bulgaria, Germany, Hungary, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026